The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Clinical & Manufacturing

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Clinical & Manufacturing

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

NOV 12, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Clinical Trial Expert Discussion: Study Design for Microbiome Therapies
Clinical & Manufacturing

Clinical Trial Expert Discussion: Study Design for Microbiome Therapies

SEP 28, 2021
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis
Clinical & Manufacturing

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis

SEP 27, 2021
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
Clinical & Manufacturing

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

SEP 20, 2021
Fecal transplant plus fibre improves insulin sensitivity in severely obese
Biotics and Supplements

Fecal transplant plus fibre improves insulin sensitivity in severely obese

JUL 6, 2021
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
Clinical & Manufacturing

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

JUN 23, 2021
New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults
Clinical & Manufacturing

New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults

JUN 15, 2021
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
Clinical & Manufacturing

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

JUN 7, 2021
Ferring and Rebiotix Present Landmark Phase 3 Data
Clinical & Manufacturing

Ferring and Rebiotix Present Landmark Phase 3 Data

MAY 24, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021